全文获取类型
收费全文 | 10817篇 |
免费 | 1046篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 111篇 |
儿科学 | 339篇 |
妇产科学 | 205篇 |
基础医学 | 1681篇 |
口腔科学 | 359篇 |
临床医学 | 1186篇 |
内科学 | 1988篇 |
皮肤病学 | 235篇 |
神经病学 | 775篇 |
特种医学 | 397篇 |
外科学 | 1456篇 |
综合类 | 236篇 |
一般理论 | 5篇 |
预防医学 | 1027篇 |
眼科学 | 195篇 |
药学 | 653篇 |
中国医学 | 14篇 |
肿瘤学 | 1012篇 |
出版年
2021年 | 128篇 |
2020年 | 96篇 |
2019年 | 129篇 |
2018年 | 166篇 |
2017年 | 133篇 |
2016年 | 148篇 |
2015年 | 177篇 |
2014年 | 216篇 |
2013年 | 403篇 |
2012年 | 499篇 |
2011年 | 510篇 |
2010年 | 295篇 |
2009年 | 287篇 |
2008年 | 439篇 |
2007年 | 522篇 |
2006年 | 473篇 |
2005年 | 450篇 |
2004年 | 460篇 |
2003年 | 433篇 |
2002年 | 395篇 |
2001年 | 319篇 |
2000年 | 360篇 |
1999年 | 302篇 |
1998年 | 128篇 |
1997年 | 114篇 |
1996年 | 88篇 |
1995年 | 102篇 |
1994年 | 88篇 |
1993年 | 99篇 |
1992年 | 290篇 |
1991年 | 261篇 |
1990年 | 221篇 |
1989年 | 242篇 |
1988年 | 172篇 |
1987年 | 208篇 |
1986年 | 198篇 |
1985年 | 217篇 |
1984年 | 139篇 |
1983年 | 134篇 |
1982年 | 100篇 |
1981年 | 86篇 |
1980年 | 86篇 |
1979年 | 141篇 |
1978年 | 92篇 |
1977年 | 93篇 |
1976年 | 95篇 |
1974年 | 88篇 |
1973年 | 96篇 |
1972年 | 94篇 |
1971年 | 97篇 |
排序方式: 共有10000条查询结果,搜索用时 20 毫秒
1.
Doreen A. Ezeife MD Francois Dionne PhD Aline Fusco Fares MD Ellen Laura Rose Cusano MD Rouhi Fazelzad BSc MISt Wenzie Ng BSc MPharm RPh Don Husereau BSc Pharm MSc Farzad Ali BPharm MSc Christina Sit MSc Barry Stein B.Com BCL LLB Jennifer H. Law MSc Lisa Le MSc Peter Michael Ellis MD MMed PhD Scott Berry MD Stuart Peacock PhD Craig Mitton PhD Craig C. Earle MD Kelvin K. W. Chan MD PhD Natasha B. Leighl MD MMSc 《Cancer》2020,126(7):1530-1540
2.
Angela J. Jacques-Tiura Deborah A. Ellis April Idalski Carcone Sylvie Naar Kathryn Brogan Hartlieb Elizabeth K. Towner Thomas N. Templin K.-L. Catherine Jen 《The Journal of adolescent health》2019,64(3):355-361
Objective
Successful weight loss interventions for African-Americans adolescents are lacking. Cognitive-behavioral interventions seek to develop weight loss skills (e.g., counting calories, goal setting, managing one's environment). Little is known about how well adolescents implement such skills in their daily lives. Study aims were to (1) examine weight loss skills utilization at midpoint and end of a 6-month cognitive-behavioral/motivational interviewing weight loss sequential multiple assignment randomized trial (SMART), and (2) determine if greater skill utilization predicted weight loss at treatment end and 3 months post-treatment.Method
One hundred and eighty six African-Americans adolescents with obesity and their caregiver were first randomly assigned to complete 3 months of cognitive-behavioral and motivational interviewing family-based weight loss treatment in their home or in the research office (Phase 1). Nonresponders (i.e., those who lost < 3% of initial weight, n?=?161) were rerandomized to 3 months of continued skills training (n?=?83) or contingency management (n?=?78) for Phase 2; responders were allocated to 3 months of relapse prevention (n?=?20). Adolescents’ frequency of weight loss skills utilization was assessed via questionnaire at treatment midpoint and end.Results
Higher treatment attendance was associated with better skill utilization. Higher skill utilization was associated with more weight loss at treatment end, whereas higher baseline confidence was associated with more weight loss at follow-up.Conclusions
This study indicates the importance of attending weight loss intervention sessions to develop and strengthen weight loss skills in African-American adolescents with obesity, and strengthening confidence to use such skills for continued weight loss. 相似文献3.
4.
5.
6.
7.
D’Amico Randy S. Khatri Deepak Reichman Noah Patel Nitesh V. Wong Tamika Fralin Sherese R. Li Mona Ellis Jason A. Ortiz Rafael Langer David J. Boockvar John A. 《Journal of neuro-oncology》2020,147(2):261-278
Journal of Neuro-Oncology - Intra-arterial (IA) delivery of therapeutic agents across the blood-brain barrier (BBB) is an evolving strategy which enables the distribution of high concentration... 相似文献
8.
Anthony W. Tolcher Razelle Kurzrock Vincente Valero Rene Gonzalez Rebecca S. Heist Antoinette R. Tan Julie Means-Powell Theresa L. Werner Carlos Becerra Chenxi Wang Cathrine Leonowens Shanker Kalyana-Sundaram Joseph F. Kleha Jennifer Gauvin Anthony M. DAmelio Catherine Ellis Nageatte Ibrahim Li Yan 《Cancer chemotherapy and pharmacology》2020,85(4):673-683
This study aimed to determine the safety, tolerability, and recommended phase II doses of trametinib plus uprosertib (GSK2141795) in patients with solid tumors likely to be sensitive to MEK and/or AKT inhibition. This was a phase I, open-label, dose-escalation, and dose-expansion study in patients with triple-negative breast cancer or BRAF-wild type advanced melanoma. The primary outcome of the expansion study was investigator-assessed response. Among 126 enrolled patients, 63 received continuous oral daily dosing of trametinib and uprosertib, 29 received various alternative dosing schedules, and 34 were enrolled into expansion cohorts. Doses tested in the expansion cohort were trametinib 1.5 mg once daily (QD) + uprosertib 50 mg QD. Adverse events (AEs) were consistent with those reported in monotherapy studies but occurred at lower doses and with greater severity. Diarrhea was the most common dose-limiting toxicity; diarrhea and rash were particularly difficult to tolerate. Overall, 59% and 6% of patients reported AEs with a maximum severity of grade 3 and 4, respectively. Poor tolerability prevented adequate delivery of uprosertib with trametinib at a concentration predicted to have clinical activity. The study was terminated early based on futility in the continuous-dosing expansion cohorts and a lack of pharmacological or therapeutic advantage with intermittent dosing. The objective response rate was < 5% (1 complete response, 5 partial responses). Continuous and intermittent dosing of trametinib in combination with uprosertib was not tolerated, and minimal clinical activity was observed in all schedules tested. 相似文献
9.
Emad A. Rakha Islam M. Miligy Cecily M. Quinn Elena Provenzano Abeer M. Shaaban Caterina Marchi Michael S. Toss Grace Gallagy Ciara Murray Janice Walshe Ayaka Katayama Karim Eldib Nahla Badr Bruce Tanchel Rebecca Millican-Slater Colin Purdie Dave Purnell Sarah E. Pinder Ian O. Ellis Andrew H. S. Lee 《British journal of cancer》2021,124(11):1836
Background The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number <4.0 signals/cell were re-classified as HER2 negative. This study aims to examine the response of Group 2 tumours to neoadjuvant chemotherapy (NACT).Methods 749 BC cases were identified from 11 institutions. The association between HER2 groups and pathological complete response (pCR) was assessed.Results 54% of immunohistochemistry HER2 positive (score 3+) BCs showed pCR, compared to 19% of immunohistochemistry 2+ FISH amplified cases. 27% of Group 2 treated with HER2 targeted therapy achieved pCR, compared to 19 and 11% in the combined Groups 1 + 3 and Groups 4 + 5, respectively. No difference in pCR rates was identified between Group 2 and Group 1 or combined Groups 1 + 3. However, Group 2 response rate was higher than Groups 4 + 5 (p = 0.017).Conclusion No difference in pCR was detected in tumours with a HER2/CEP17 ratio ≥2.0 and a HER2 score 2+ by IHC when stratified by HER2 gene copy number. Our data suggest that ASCO/CAP HER2 Group 2 carcinomas should be evaluated further with respect to eligibility for HER2 targeted therapy.Subject terms: Breast cancer, Breast cancer 相似文献
10.
Cary Jo R. Schlick Ryan J. Ellis Ryan P. Merkow Anthony D. Yang David J. Bentrem 《HPB : the official journal of the International Hepato Pancreato Biliary Association》2021,23(5):723-732
BackgroundPost-discharge venous thromboembolism (VTE) chemoprophylaxis decreases VTEs following cancer surgery, however identifying high-risk patients remains difficult. Our objectives were to (1) identify factors available at hospital discharge associated with post-discharge VTE following hepatectomy for malignancy and (2) develop and validate a post-discharge VTE risk calculator to evaluate patient-specific risk.MethodsPatients who underwent hepatectomy for malignancy from 2014 to 2017 were identified from the ACS NSQIP hepatectomy procedure targeted module. Multivariable logistic regression identified factors associated with post-discharge VTE. A post-discharge VTE risk calculator was constructed, and predicted probabilities of post-discharge VTE were calculated.ResultsAmong 11 172 patients, 95 (0.9%) developed post-discharge VTE. Post-discharge VTE was associated with obese BMI (OR 2.29 vs. normal BMI [95%CI 1.31–3.99]), right hepatectomy/trisegmentectomy (OR 1.63 vs. partial/wedge [95%CI 1.04–2.57]), and several inpatient postoperative complications: renal insufficiency (OR 5.29 [95%CI 1.99–14.07]), transfusion (OR 1.77 [95%CI 1.12–2.80]), non-operative procedural intervention (OR 2.97 [95%CI 1.81–4.86]), and post-hepatectomy liver failure (OR 2.22 [95%CI 1.21–4.08]). Post-discharge VTE risk ranged from 0.3% to 30.2%. Twenty iterations of 10-fold cross validation identified internal validity.ConclusionsRisk factors from all phases of care, including inpatient complications, are associated with post-discharge VTE following hepatectomy. Identifying high-risk patients may allow for personalized risk-based post-discharge chemoprophylaxis prescribing. 相似文献